Compare HLIO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | PVLA |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1996 | 2013 |
| Metric | HLIO | PVLA |
|---|---|---|
| Price | $68.51 | $131.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $94.67 | ★ $228.93 |
| AVG Volume (30 Days) | ★ 350.8K | 191.6K |
| Earning Date | 11-02-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | 23.93 | ★ 52.62 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $200,727,000.00 | $42,810,000.00 |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $5.86 | N/A |
| P/E Ratio | $55.10 | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $49.00 | $68.96 |
| 52 Week High | $95.05 | $161.38 |
| Indicator | HLIO | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 38.49 |
| Support Level | $66.25 | $109.68 |
| Resistance Level | $69.41 | $135.23 |
| Average True Range (ATR) | 1.78 | 7.02 |
| MACD | 0.25 | -0.51 |
| Stochastic Oscillator | 27.77 | 24.37 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.